Literature DB >> 20616586

Depiction of portal supply in early hepatocellular carcinoma and dysplastic nodule: value of pure arterial ultrasound imaging in hepatocellular carcinoma.

Masatoshi Kudo1, Kinuyo Hatanaka, Tatsuo Inoue, Kiyoshi Maekawa.   

Abstract

Ultrasound (US) contrast agents such as SonoVue and Sonazoid are commercially available worldwide. Innovation of contrast agents and advances of new US technologies have dramatically changed both diagnostic and treatment strategies for hepatocellular carcinoma (HCC). Recently, the breakthrough technique, pure arterial phase (PAP) US imaging, which depicts only intranodular arterial supply by use of maximum intensity projection (MIP) images, was developed from advanced raw data-storing and accumulation technologies. A total of 8 dysplastic nodules (DNs), 16 early HCCs, 5 nodule-in-nodule type early HCCs and 48 overt HCCs were included in this study. All 8 DNs (100%) showed arterial hypovascularity in the PAP followed by preserved portal perfusion at the portal phase and isouptake at the Kupffer phase by Sonazoid-enhanced contrast US. A total of 12 out of 16 early HCCs (75%) showed similar patterns on vascular and Kupffer phase imaging of contrast-enhanced ultrasonography. The remaining 4 HCCs showed slightly hypervascular pattern without venous washout and slightly decreased Kupffer uptake. All 5 nodule-in-nodule type early HCCs presented partial arterial enhancement within hypovascular nodule at the PAP followed by isovascular pattern at the portal phase and partial Kupffer defect within isouptake nodules. All 48 overt HCCs showed a hypervascular pattern with Kupffer defect on contrast-enhanced ultrasonography. This technique can clearly identify whether blood supply in the tumor is of arterial or portal origin, and facilitate the noninvasive characterization of nodular lesions associated with liver cirrhosis. In conclusion, this newly developed innovative technique can depict pure portal supply in early HCC and DN, enabling differentiating premalignant lesions and early HCCs from overt HCC even though dynamic CT or MRI does not have such capabilities. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616586     DOI: 10.1159/000315232

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-12-15       Impact factor: 11.740

Review 2.  Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma.

Authors:  Jeong Min Lee; Jeong-Hee Yoon; Ijin Joo; Hyun Sik Woo
Journal:  Liver Cancer       Date:  2012-06       Impact factor: 11.740

3.  Early hemodynamics of hepatocellular carcinoma using contrast-enhanced ultrasound with Sonazoid: focus on the pure arterial and early portal phases.

Authors:  Akiko Saito; Masakazu Yamamoto; Satoshi Katagiri; Shingo Yamashita; Masayuki Nakano; Toshio Morizane
Journal:  Glob Health Med       Date:  2020-10-31

4.  Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt.

Authors:  Yuo-Chen Kuo; Maureen P Kohi; David M Naeger; Ricky T Tong; K Pallav Kolli; Andrew G Taylor; Jeanne M Laberge; Robert K Kerlan; Nicholas Fidelman
Journal:  Cardiovasc Intervent Radiol       Date:  2013-07-18       Impact factor: 2.740

Review 5.  Vessel co-option in cancer.

Authors:  Elizabeth A Kuczynski; Peter B Vermeulen; Francesco Pezzella; Robert S Kerbel; Andrew R Reynolds
Journal:  Nat Rev Clin Oncol       Date:  2019-08       Impact factor: 66.675

Review 6.  Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.

Authors:  Hitoshi Maruyama; Tadashi Sekimoto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2015-12-22       Impact factor: 6.772

7.  Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined?

Authors:  Hyo-Jin Kang; Jung Hoon Kim; Jeongin Yoo; Joon Koo Han
Journal:  Ultrasonography       Date:  2021-12-17

8.  Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.

Authors:  Takuji Torimura; Hideki Iwamoto; Toru Nakamura; Mitsuhiko Abe; Yu Ikezono; Fumitaka Wada; Takahiko Sakaue; Hiroshi Masuda; Osamu Hashimoto; Hironori Koga; Takato Ueno; Hirohisa Yano
Journal:  Neoplasia       Date:  2016-07       Impact factor: 5.715

Review 9.  How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis.

Authors:  Hyun Jeong Park; Byung Ihn Choi; Eun Sun Lee; Sung Bin Park; Jong Beum Lee
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.